With me today are Robert Ford, Chairman and Chief Executive Officer, and Philip Boudreau, Executive Vice President, Finance ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) fell short of the markets revenue expectations in Q4 ...

Intel shares slip ahead of the chip maker’s fourth-quarter earnings, due out after the close of trading Thursday.

Jan 22 (Reuters) - Abbott forecast current-quarter profit below estimates after missing Wall Street expectations for ...

For the current quarter ending in March, Abbott expects its per-share earnings to range from $1.12 to $1.18. The company ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

The medical device maker announced it anticipates first quarter adjusted profits per share between $1.12 and $1.18, trailing ...

For the year, Abbott forecast organic sales growth in the range of 6.5% to 7.5%, the midpoint of which missed Wall Street ...

Abbott Laboratories (ABT) stock falls as underperformance in the company's Nutrition segment leads it to record lower than expected Q4 sales. Read more here.

Abbott missed Wall Street estimates for quarterly revenue on Thursday, hit by weakness in its diagnostic business which has been volatile due to sharp decline in COVID-19 testing demand and a freeze ...

Abbott’s stock has fallen by over 7% despite reporting strong fiscal year 2025 (FY25) revenues of $44.32bn, representing a ...

Abbott Laboratories stock has reached a 52-week low, closing at $107.27. This marks a notable point for the healthcare company, as it navigates a challenging market environment. Over the past year, ...